Wandeler G, et al. - In a large multi-cohort study involving 3,625 patients, researchers assessed the incidence and risk factors of hepatocellular carcinoma (HCC) among HIV/hepatitis B virus-coinfected people on a tenofovir disoproxil fumarate (TDF)-containing antiretroviral therapy. All HIV-infected adults with a positive hepatitis B surface antigen test followed in four prospective European cohorts were included. To evaluate HCC risk factors, multivariable Poisson regression was utilized. Over 32,673 patient-years, 60 people (1.7%) developed HCC. Predictors of HCC were age at start of TDF and the presence of liver cirrhosis. Among individuals on TDF, HCC incidence stayed stable over time; among those not on TDF, it increased steadily. According to findings, the incidence of HCC stayed below the HCC screening threshold in non-cirrhosis patients who began TDF at <46 years of age; in cirrhotic HIV/HBV-coinfected individuals, the incidence of HCC was high.